Profile data is unavailable for this security.
About the company
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
- Revenue in CAD (TTM)68.16m
- Net income in CAD23.64m
- Incorporated2020
- Employees61.00
- LocationCipher Pharmaceuticals Inc5750 Explorer Drive,, Suite 404MISSISSAUGA L4W 0A9CanadaCAN
- Phone+1 (905) 602-5840
- Websitehttps://www.cipherpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medexus Pharmaceuticals Inc | 135.40m | -370.38k | 92.41m | 91.00 | -- | 1.30 | 7.19 | 0.6825 | -0.0142 | -0.0142 | 4.25 | 2.20 | 0.6608 | 1.40 | 7.68 | 1,487,904.00 | -0.1808 | -3.71 | -0.3159 | -6.22 | 53.87 | 52.71 | -0.2736 | -5.74 | 0.6197 | 1.23 | 0.3268 | -- | -4.18 | 14.31 | 1,150.00 | -- | 24.90 | -- |
| Charlotte's Web Holdings Inc | 67.05m | -29.53m | 167.79m | 112.00 | -- | 13.27 | -- | 2.50 | -0.1861 | -0.1861 | 0.4222 | 0.0791 | 0.4893 | 1.39 | 36.51 | 598,637.40 | -21.55 | -28.40 | -24.66 | -32.20 | 44.26 | 46.82 | -44.04 | -74.38 | 1.65 | -6.81 | 0.8408 | -- | -21.36 | -12.09 | -25.42 | -- | -23.86 | -- |
| Auxly Cannabis Group Inc | 146.00m | 45.34m | 170.88m | 388.00 | 4.07 | 0.977 | 3.05 | 1.17 | 0.0307 | 0.0307 | 0.1019 | 0.1279 | 0.5401 | 1.75 | 6.63 | 376,275.80 | 16.77 | -18.35 | 22.80 | -23.05 | 52.00 | 26.34 | 31.05 | -72.02 | 1.05 | 3.07 | 0.2767 | -- | 21.02 | 71.06 | 63.27 | -- | -40.74 | -- |
| Biosyent Inc | 42.18m | 8.63m | 171.33m | 0.00 | 19.96 | 4.21 | 14.69 | 4.06 | 0.7479 | 0.7479 | 3.65 | 3.54 | 0.9045 | 1.64 | 8.01 | -- | 18.52 | 15.49 | 21.83 | 17.84 | 77.46 | 79.98 | 20.47 | 20.11 | 4.23 | -- | 0.0219 | 15.57 | 10.89 | 10.33 | 12.54 | 10.72 | -39.09 | -- |
| Aurora Cannabis Inc | 373.12m | -88.26m | 276.17m | 1.10k | -- | 0.5149 | -- | 0.7402 | -1.57 | -1.58 | 6.64 | 9.46 | 0.4545 | 1.52 | 7.96 | 338,890.10 | -11.73 | -- | -15.10 | -- | 1.35 | -- | -25.80 | -- | 1.48 | -- | 0.151 | -- | 27.32 | -- | 130.82 | -- | -- | -- |
| Cipher Pharmaceuticals Inc | 68.16m | 23.64m | 369.12m | 61.00 | 16.35 | 2.39 | 11.16 | 5.42 | 0.8928 | 0.8928 | 2.57 | 6.12 | 0.3322 | 2.15 | 4.29 | 1,117,375.00 | 11.52 | 19.63 | 13.03 | 23.17 | 74.32 | 79.74 | 34.69 | 59.54 | 0.9766 | 5.74 | 0.1052 | 0.00 | 57.66 | 8.24 | -43.36 | 34.34 | 127.59 | -- |
| Spectral Medical Inc | 2.71m | -41.69m | 380.33m | 29.00 | -- | -- | -- | 140.60 | -0.1455 | -0.1456 | 0.0095 | -0.2375 | 0.331 | 4.43 | 7.03 | 93,275.86 | -510.19 | -135.57 | -- | -711.89 | 56.16 | 55.19 | -1,541.33 | -581.02 | 0.1044 | -0.1904 | -- | -- | 43.05 | -4.43 | 0.7223 | -- | -30.03 | -- |
| Canopy Growth Corp | 278.39m | -327.29m | 598.10m | 960.00 | -- | 0.7189 | -- | 2.15 | -1.85 | -1.84 | 1.16 | 2.06 | 0.2452 | 2.08 | 7.59 | 289,988.50 | -28.83 | -30.76 | -31.54 | -33.95 | 26.56 | 8.54 | -117.57 | -315.36 | 4.26 | -0.1761 | 0.2518 | -- | -9.47 | -7.57 | -24.90 | -- | -56.47 | -- |
| Knight Therapeutics Inc | 413.85m | -3.49m | 623.99m | 745.00 | -- | 0.8216 | 12.01 | 1.51 | -0.0378 | -0.0378 | 4.12 | 7.69 | 0.4116 | 1.84 | 3.96 | 555,498.00 | -0.3474 | 0.0976 | -0.4015 | 0.1143 | 42.49 | 46.11 | -0.844 | 0.351 | 1.68 | -- | 0.1217 | 0.00 | 13.13 | 50.90 | 125.73 | -21.48 | 60.58 | -- |
| DRI Healthcare Trust | 192.69m | -52.24m | 881.18m | 36.00 | -- | 2.02 | 17.71 | 4.57 | -0.9453 | -0.9453 | 3.45 | 7.93 | 0.2149 | -- | 3.91 | 5,352,556.00 | -5.83 | -- | -6.38 | -- | -- | -- | -27.11 | -- | -- | 1.82 | 0.5077 | -- | 16.24 | -- | -103.68 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Huber Capital Management LLCas of 31 Oct 2025 | 224.70k | 0.89% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 88.19k | 0.35% |
| Maxam Capital Management Ltd.as of 30 Jun 2025 | 45.00k | 0.18% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 12.34k | 0.05% |
| Tralucent Asset Management, Inc.as of 30 Jun 2025 | 8.82k | 0.04% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2025 | 5.83k | 0.02% |
| DFA Australia Ltd.as of 31 Dec 2025 | 1.54k | 0.01% |
| Hotchkis & Wiley Capital Management LLCas of 31 Dec 2025 | 1.00k | 0.00% |
